Nasdaq
Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4
Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases
Ceribell Pursues $101M Nasdaq IPO for Revolutionary Seizure-Spotting Headset
Ceribell, Seizure-Spotting Headset, Nasdaq IPO, Emergency Seizure Care, Brain-Reading Technology
MBX Biosciences Enters IPO Queue Amid End-of-Summer Rush
MBX Biosciences, IPO, NASDAQ, peptide therapeutics, biotech, public offering
Grifols Founding Family and Brookfield Plan to Take Drugmaker Private
Grifols, Brookfield, Private Equity, Takeover Bid, Spanish Drugmaker, Nasdaq, Spanish Stock Exchange
Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings
Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings